Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.

CMP Therapeutics has developed a treatment for regulating and stimulating the immune system. The lead product is in Phase II clinical trials for allergic disorders. Other pipeline products have shown through stimulation of the immune system to protect against viruses and bacteria.

Asterion is a manufacturer of analog semiconductors.

Icagen partners with pharmaceutical and biotechnology companies to offer scientific expertise and access to technologies for ion channel and transporter drug discovery and development. The Icagen team has experience advancing molecules from drug discovery to clinical development across multiple therapeutic areas and ion channel classes. Icagen's tool box comprises a range of cell lines and technologies for ion channel and transporter research, capped by the label-free XRpro platform. XRpro technology, based on X-ray fluorescence, enables high throughput assessment of ion channels and transporters, including challenging systems with high therapeutic interest.